Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

The launch of Almirall’s eczema treatment, Ebglyss (lebrikizumab), generated $22 million in sales across initial European markets, while Ilumetri (tildrakizumab) for psoriasis saw sales rise 24.8% ...